NLRP3 Modulators Enhancing Immune Response in Low T-Cell Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers with low T-cell infiltration are ineffective due to insufficient immune response, as they do not adequately enhance NLRP3 signaling to correct innate immune activity deficiencies.
Innovation Solution
Development of compounds that modulate NLRP3 activity by agonizing or partially agonizing the NLRP3 inflammasome, which are administered alone or in combination with other cancer therapies to enhance immune response in cancers with low CD8+ T-cell infiltration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then treatment is administered to patients, but the treatment is ineffective in cancers with low T-cell infiltration due to insufficient immune response
Solution Approach 1:
The patent applies parameter changes by modifying the immunological state of the tumor microenvironment through NLRP3 activation. The compounds change key parameters such as inflammatory cytokine levels (IL-1β, IL-18), immune cell infiltration (CD8+ T cells, NK cells), and tumor immunogenicity, transforming the tumor from an immunosuppressive state to an immunoreactive state that responds to cancer therapy.
Solution Approach 2:
The patent uses NLRP3 inflammasome as an intermediary mechanism to bridge conventional cancer therapies and the immune system. The NLRP3-activating compounds serve as mediators that trigger inflammatory responses and immune cell recruitment, thereby enhancing the effectiveness of therapies that rely on immune-mediated tumor destruction.
2Adaptability or versatility
If NLRP3 signaling is increased to correct innate immune activity deficiencies, then immune response is enhanced, but this requires development of new compound classes beyond conventional therapies
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (Formula I) that target and activate the NLRP3 inflammasome. The structural parameters of these compounds (substituents R1-R6, linkers Y, heteroaryl groups) are optimized to achieve potent NLRP3 activation while maintaining drug-like properties, thereby enhancing immunity through a defined chemical mechanism.
3Reliability
If compounds are developed to agonize NLRP3 inflammasome, then treatment efficacy is improved in cancers resistant to conventional therapies, but this requires combination with other cancer therapies
Solution Approach 1:
The patent applies merging by combining NLRP3-activating compounds with conventional cancer therapies (chemotherapy, radiation, immunotherapy) to create synergistic treatment regimens. The NLRP3 activation merges with existing therapeutic mechanisms to produce enhanced anti-tumor effects that overcome resistance to single-agent therapies.
Data Source
AI summary
The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).